肥胖是世界范围内一个突出的健康问题，直接影响胰腺健康，肥胖个体表现出增加胰腺导管腺癌（PDAC）的显着风险。有几个因素可能解释 PDAC 发生风险增加的原因，包括肥胖引起的胰腺内外慢性炎症、胰岛素抵抗和代谢功能障碍的发生、炎症、前期和恶性阶段期间胰腺内免疫抑制的促进，脂肪组织产生的激素水平（脂联素、生长素释放肽和瘦素）的变化，以及对胰腺肿瘤发生至关重要的肿瘤一次性蛋白和抑制蛋白的体细胞突变的获得。在这篇手稿中，我们将探讨这些肥胖引起的危险因素对 PDAC 发生和进展的广泛影响，重点关注肿瘤微环境 (TME) 内的变化，因为它们与预防、当前的治疗策略和未来的靶向方向有关。肥胖管理，因为它们与预防胰腺肿瘤发生有关。版权所有 © 2023 Elsevier Ltd. 保留所有权利。

Obesity is a prominent health issue worldwide and directly impacts pancreatic health, with obese individuals exhibiting a significant risk for increasing pancreatic ductal adenocarcinoma (PDAC). Several factors potentially explain the increased risk for the development of PDAC, including obesity-induced chronic inflammation within and outside of the pancreas, development of insulin resistance and metabolic dysfunction, promotion of immune suppression within the pancreas during inflammation, pre- and malignant stages, variations in hormones levels (adiponectin, ghrelin, and leptin) produced from the adipose tissue, and acquisition of somatic mutations in tumor once- and suppressor proteins critical for pancreatic tumorigenesis. In this manuscript, we will explore the broad impact of these obesity-induced risk factors on the development and progression of PDAC, focusing on changes within the tumor microenvironment (TME) as they pertain to prevention, current therapeutic strategies, and future directions for targeting obesity management as they relate to the prevention of pancreatic tumorigenesis.Copyright © 2023 Elsevier Ltd. All rights reserved.